Patents by Inventor Mark Reid
Mark Reid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11564988Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 9, 2019Date of Patent: January 31, 2023Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20220387768Abstract: A balloon catheter is provided with a main tube and an air tube therein. The main tube is provided with a central lumen to allow the balloon catheter to travel across and be guided along a guidewire during insertion into a vasculature of a patient. The air tube is configured to transfer fluid, such as air, to a balloon for inflating and deflating the balloon. The air tube can be embedded within the inner and outer surfaces of the main tube. Holes are cut into the main tube and a portion of the air tube to expose the air tube to the environment outside of the main tube. The holes allow for fluid communication between the air tube and the balloon. The holes are cut or sheared at a direction that is lateral to the longitudinal direction of the catheter tube.Type: ApplicationFiled: June 4, 2021Publication date: December 8, 2022Inventors: Mark REID, Andrew ENGLISH, Orlagh MCNALLY, Kyle FLANAGAN
-
Patent number: 11219616Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: December 23, 2019Date of Patent: January 11, 2022Assignees: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20200338050Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: December 23, 2019Publication date: October 29, 2020Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Publication number: 20200061196Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: September 9, 2019Publication date: February 27, 2020Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 10517854Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.Type: GrantFiled: September 18, 2017Date of Patent: December 31, 2019Assignees: 60 Degrees Pharmaceuticals LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 10406236Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: April 24, 2017Date of Patent: September 10, 2019Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20180064693Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I):A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV-4 viral infections.Type: ApplicationFiled: September 18, 2017Publication date: March 8, 2018Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong OOI, Jenny Low
-
Publication number: 20170297912Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: April 24, 2017Publication date: October 19, 2017Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 9763921Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: GrantFiled: March 14, 2014Date of Patent: September 19, 2017Assignees: 60 Degrees Pharmaceuticals LLC, Singapore Health Services PTE LTD, National University Of SingaporeInventors: Geoffrey S. Dow, Subhash Vasudevan, Mark Reid, Glynn Morrish, Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi, Jenny Low
-
Patent number: 9629927Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: GrantFiled: September 23, 2013Date of Patent: April 25, 2017Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Publication number: 20160030403Abstract: Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicants: 60 Degrees Pharmaceuticals, LLC, National University of Singapore, Singapore Health Services PTE Ltd.Inventors: Geoffrey S. DOW, Subhash VASUDEVAN, Mark REID, Glynn MORRISH, Cynthia SUNG, Abhay RATHORE, Satoru WATANABE, Eng Eong OOI, Jenny LOW
-
Patent number: 8729274Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.Type: GrantFiled: March 9, 2010Date of Patent: May 20, 2014Assignee: Merck Sharp & Dohme B.V.Inventors: Keneth Davies, Takao Kiyoi, Ashvinkumar Dhirubhai Mistry, Peter Christopher Ray, Mark Reid, Grant Wishart
-
Publication number: 20140086831Abstract: The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.Type: ApplicationFiled: September 23, 2013Publication date: March 27, 2014Inventors: David A. Scheinberg, Michael R. McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jon Njardarson, Mark Reid Phillips
-
Patent number: 8540965Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.Type: GrantFiled: July 31, 2006Date of Patent: September 24, 2013Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael McDevitt, Christophe Antczak, Debjit Chattopadhyay, Rena May, Jón Njardarson, Mark Reid Philips
-
Publication number: 20120232122Abstract: The present invention relates to a tricyclic heterocyclic derivative according to Formula (I), wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to pharmaceutical compositions comprising said tricyclic heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of serotonin mediated disorders, such as obesity.Type: ApplicationFiled: March 9, 2010Publication date: September 13, 2012Inventors: Keneth Davies, Takao Kiyoi, Ashvinkumar Dhirubhai Mistry, Peter Christopher Ray, Mark Reid, Grant Wishart
-
Publication number: 20120086906Abstract: An apparatus and system for alleviating the symptoms of scotopic sensitivity syndrome for a user wearing eyeglasses is provided. The eyewear comprises one or more layers, a first band, and a second band. Each of the layers comprises a coloured film. The first and second bands are attached to the one or more layers. When the eyewear is in use, the one or more layers are placed in front of the eyeglasses and the first band is attached to the second band at a location behind the user's head. Systems for assisting in viewing a computer screen or printed matter are also provided.Type: ApplicationFiled: October 7, 2011Publication date: April 12, 2012Inventor: Mark Reid
-
Publication number: 20090304581Abstract: The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.Type: ApplicationFiled: July 31, 2006Publication date: December 10, 2009Inventors: David A. Scheinberg, Michael McDevitt, Debjit Chattopadhyay, Mark Reid Philips
-
Publication number: 20080022071Abstract: A computerized system for simultaneous operation of multiple environments and method for storing distinct data types separately is disclosed. The computerized system includes a plurality of main host, sub-host, data storage and network devices wherein data of a first type is stored on main host, data storage and network devices and data of a second type is stored on one of the sub-host, data storage and network devices, wherein data of a third type is stored on at least another one of the sub-host, data storage and network devices, and data of a forth type is stored on at least another one of the sub-host, data storage and network devices, wherein all of the data types requires controlling access thereto. The invention provides for ensuring the integrity and separation of the data stored on the sub-host, data storage and network devices. It also prevents misappropriation of data stored on the devices.Type: ApplicationFiled: June 28, 2004Publication date: January 24, 2008Inventor: Mark Reid
-
Publication number: 20050251547Abstract: Method, apparatus and computer program product are provided to increase the efficiency of copy operations in a data storage system. Multiple virtual storage controllers are each in communication with a host device and to two virtual storage servers. Both virtual storage servers are attached to a respective automated storage library. Each controller includes a copy queue. After directing that a volume of customer data be stored through one of the servers on media in the associated library, an initiating controller queues in a copy queue a request to copy the volume to the other library. If the request is not processed by the initiating controller within a very short period, the initiating controller broadcasts the copy request to the other controllers. Preferably, the copy request is transmitted first from the initiating controller to a routing device in one of the servers which broadcasts the request to each other controller. The copy request is queued in a copy queue of each other controller.Type: ApplicationFiled: May 5, 2004Publication date: November 10, 2005Applicant: International Business Machines (IBM) CorporationInventors: Keith Bello, Dean Hanson, Mark Reid